Medicus Pharma Advances SkinJect D-MNA and Teverelix Programs After Positive Phase 2 Findings

Positive Phase 2 clearance data from Medicus Pharma's microneedle array platform is now shaping the company's regulatory engagement strategy, with manufacturing and clinical operations teams facing near-term decisions on registrational pathway design. The Q1 2026 update, reported May 14, confirms that the SKNJCT-003 study reached full enrollment at 90 patients and generated what the company characterizes as decision-grade, expanded dataset findings in nodular basal cell carcinoma.

The 200-µg cohort of the Doxorubicin Microneedle Array (D-MNA) demonstrated positive dose-response trends and registrational-grade clearance rates, a threshold that typically triggers pre-NDA or Type B meeting requests under 21 CFR Part 312 end-of-Phase 2 guidance. Medicus has indicated it intends to continue FDA engagement on potential registrational development pathways, a signal that CMC documentation, process validation packages, and sterility assurance protocols for the microneedle array format will require alignment with current GMP expectations before any pivotal study can be initiated.

In parallel, the Teverelix® GnRH antagonist program received FDA clearance to initiate a Phase 2b dose optimization study in advanced prostate cancer. A second protocol, targeting acute urinary retention recurrence prevention, has been submitted for review. Both programs were advanced following Medicus's acquisition of Antev Limited, which brought Teverelix into the portfolio as a long-acting injectable candidate for cardiovascular high-risk prostate cancer patients.

On the regulatory affairs side, Medicus submitted an Orphan Drug Designation application to the FDA for SkinJect in Gorlin Syndrome, a rare autosomal dominant condition also classified as nevoid basal cell carcinoma syndrome. Orphan designation, if granted, would carry seven-year market exclusivity and eligibility for accelerated approval pathways, both of which carry downstream implications for labeling strategy and post-approval commitments. The company also continued geographic expansion through the SKNJCT-004 study in the UAE.

The company's AI-enabled clinical development capabilities and expanded financing arrangements were cited as supporting infrastructure for multiple concurrent programs, though no specific platform details were disclosed in the Q1 release.

The next measurable checkpoint for QA and regulatory teams will be the outcome of FDA engagement on registrational pathway options for the 200-µg D-MNA cohort, which will determine the scope of process validation and analytical method transfer requirements ahead of any pivotal manufacturing scale-up.

Source: Medicus Pharma Ltd. via GlobeNewswire, May 14, 2026.